Metastatic Pancreatic Ductal Adenocarcinoma
2 competing products in clinical development for Metastatic Pancreatic Ductal Adenocarcinoma.
Pipeline by Phase
Phase 11
Phase 1/21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| CD40 agonist mitazalimab in combination with chemotherapy | Alligator Bioscience AB | Phase 1/2 | Active | 26 |
| Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine | Lonza | Phase 1 | Terminated | 18 |